Scientific Resources A Phase 1/1b Study of the Tumor-Activated IL-2 Prodrug WTX-124 Alone or in Combination with Pembrolizumab in Patients with Immunotherapy-Sensitive Locally Advanced or Metastatic Solid Tumors (Presented as a poster at SITC 2023 Annual Meeting) 5.3 MB Spatial Analysis of Tumor Infiltrating Lymphocyte Populations in Syngeneic Mouse Tumor Models After Treatment with IL-12 (mWTX-330) and IL-2 (WTX-124) INDUKINETM Molecules (Presented as a poster at SITC 2023 Annual Meeting) 4.6 MB Development of WTX-712, a Conditionally Activated IL-21 INDUKINETM Molecule for the Treatment of Cancer (Presented as a poster at SITC 2023 Annual Meeting) 2.4 MB The Combination of ACT and INDUKINETM Therapy Leads to Improved Antitumor Immunity in Solid Tumors (Presented as a poster at SITC 2023 Annual Meeting) 1.8 MB Optimal Antitumor Immunity Triggered by WTX-124, a Clinical Stage Conditionally Activated INDUKINETM Molecule that Releases Fully Potent IL-2 in the Tumor Microenvironment (Presented as a poster at SITC 2023 Annual Meeting) 4.3 MB PK/RO Modeling of WTX-124, a Tumor-Activated IL-2 Prodrug, Highlights the Potential for a Substantially Improved Therapeutic Index Compared to Other IL-2 Molecules (Presented as a poster at SITC 2023 Annual Meeting) 7.6 MB mWTX-330, an IL 12 INDUKINE Molecule, Activates and Reshapes Tumor-infiltrating… Generation of IL-21 INDUKINETM Molecules for the Treatment of Cancer (Poster presentated at AACR 2023) 1.1 MB A first-in-human, phase 1, multicenter dose escalation and dose expansion study of WTX-330 in adult patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma (Poster presented at AACR 2023) 1.5 MB A multicenter phase 1/1b dose escalation study of WTX-124 as a monotherapy and in combination with pembrolizumab in patients with selected advanced or metastatic solid tumors (Poster presented at AACR 2023) 1.4 MB Current page 1 Page 2 Next page › Last page »
A Phase 1/1b Study of the Tumor-Activated IL-2 Prodrug WTX-124 Alone or in Combination with Pembrolizumab in Patients with Immunotherapy-Sensitive Locally Advanced or Metastatic Solid Tumors (Presented as a poster at SITC 2023 Annual Meeting) 5.3 MB
Spatial Analysis of Tumor Infiltrating Lymphocyte Populations in Syngeneic Mouse Tumor Models After Treatment with IL-12 (mWTX-330) and IL-2 (WTX-124) INDUKINETM Molecules (Presented as a poster at SITC 2023 Annual Meeting) 4.6 MB
Development of WTX-712, a Conditionally Activated IL-21 INDUKINETM Molecule for the Treatment of Cancer (Presented as a poster at SITC 2023 Annual Meeting) 2.4 MB
The Combination of ACT and INDUKINETM Therapy Leads to Improved Antitumor Immunity in Solid Tumors (Presented as a poster at SITC 2023 Annual Meeting) 1.8 MB
Optimal Antitumor Immunity Triggered by WTX-124, a Clinical Stage Conditionally Activated INDUKINETM Molecule that Releases Fully Potent IL-2 in the Tumor Microenvironment (Presented as a poster at SITC 2023 Annual Meeting) 4.3 MB
PK/RO Modeling of WTX-124, a Tumor-Activated IL-2 Prodrug, Highlights the Potential for a Substantially Improved Therapeutic Index Compared to Other IL-2 Molecules (Presented as a poster at SITC 2023 Annual Meeting) 7.6 MB
Generation of IL-21 INDUKINETM Molecules for the Treatment of Cancer (Poster presentated at AACR 2023) 1.1 MB
A first-in-human, phase 1, multicenter dose escalation and dose expansion study of WTX-330 in adult patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma (Poster presented at AACR 2023) 1.5 MB
A multicenter phase 1/1b dose escalation study of WTX-124 as a monotherapy and in combination with pembrolizumab in patients with selected advanced or metastatic solid tumors (Poster presented at AACR 2023) 1.4 MB
